PT  - JOURNAL ARTICLE
AU  - Bos, Maxime M
AU  - Goulding, Neil J
AU  - Lee, Matthew A
AU  - Hofman, Amy
AU  - Bot, Mariska
AU  - Pool, René
AU  - Vijfhuizen, Lisanne S
AU  - Zhang, Xiang
AU  - Li, Chihua
AU  - Mustafa, Rima
AU  - Neville, Matt J
AU  - Li-Gao, Ruifang
AU  - Trompet, Stella
AU  - Beekman, Marian
AU  - Biermasz, Nienke R
AU  - Boomsma, Dorret I
AU  - Boer, Irene de
AU  - Christodoulides, Constantinos
AU  - Dehghan, Abbas
AU  - Dijk, Ko Willems van
AU  - Ford, Ian
AU  - Gao, He
AU  - Ghanbari, Mohsen
AU  - Heijmans, Bastiaan T
AU  - Ikram, M Arfan
AU  - Jukema, J Wouter
AU  - Mook-Kanamori, Dennis O
AU  - Karpe, Fredrik
AU  - Luik, Annemarie I
AU  - Lumey, L.H.
AU  - van den Maagdenberg, Arn M.J.M.
AU  - Mooijaart, Simon P
AU  - Mutsert, Renée de
AU  - Penninx, Brenda W.J.H.
AU  - Rensen, Patrick CN
AU  - Richmond, Rebecca C
AU  - Rosendaal, Frits R
AU  - Sattar, Naveed
AU  - Schoevers, Robert A
AU  - Slagboom, P Eline
AU  - Terwindt, Gisela M
AU  - Thesing, Carisha S
AU  - Wade, Kaitlin H
AU  - Wijsman, Carolien A
AU  - Willemsen, Gonneke
AU  - Zwinderman, Aeilko H.
AU  - Heemst, Diana van
AU  - Noordam, Raymond
AU  - Lawlor, Deborah A
TI  - Investigating the relationships between unfavorable sleep and metabolomic traits: evidence from multi-cohort multivariable regression and Mendelian randomization analyses
AID  - 10.1101/2020.08.27.20173518
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.27.20173518
4099  - http://medrxiv.org/content/early/2020/09/01/2020.08.27.20173518.short
4100  - http://medrxiv.org/content/early/2020/09/01/2020.08.27.20173518.full
AB  - Background Sleep traits are associated with cardiometabolic disease risk, with evidence from Mendelian randomization (MR) suggesting that insomnia symptoms and shorter sleep duration increase coronary artery disease risk. We combined adjusted multivariable regression (AMV) and MR analyses of phenotypes of unfavourable sleep on 113 metabolomic traits to investigate possible biochemical mechanisms linking sleep to cardiovascular disease.Methods We used AMV (N=17,370) combined with two-sample MR (N=38,618) to examine effects of self-reported insomnia symptoms, total habitual sleep duration, and chronotype on 113 metabolomic traits. The AMV analyses were conducted on data from 10 cohorts of mostly Europeans, adjusted for age, sex and body mass index. For the MR analyses, we used summary results from published European-ancestry genome-wide association studies of self-reported sleep traits and of nuclear magnetic resonance (NMR) serum metabolites. We used the inverse-variance weighted (IVW) method and complemented this with sensitivity analyses to assess MR assumptions.Results We found consistent evidence from AMV and MR analyses for associations of usual vs. sometimes/rare/never insomnia symptoms with lower citrate (−0.08 standard deviation (SD)[95% confidence interval (CI): −0.12, −0.03] in AMV and −0.03SD [−0.07, −0.003] in MR), higher glycoprotein acetyls (0.08SD [95%CI: 0.03, 0.12] in AMV and 0.06SD [0.03, 0.10) in MR]), lower total very large HDL particles (−0.04SD [−0.08, 0.00] in AMV and - 0.05SD [−0.09, −0.02] in MR) and lower phospholipids in very large HDL particles (−0.04SD [−0.08, 0.002] in AMV and −0.05SD [−0.08, −0.02] in MR). Longer total sleep duration associated with higher creatinine concentrations using both methods (0.02SD per 1-hour [0.01, 0.03] in AMV and 0.15SD [0.02, 0.29] in MR) and with isoleucine in MR analyses (0.22SD [0.08, 0.35]). No consistent evidence was observed for effects of chronotype on metabolomic measures.Conclusions Whilst our results suggested that unfavourable sleep traits may not cause widespread metabolic disruption, some notable effects were observed. The evidence for possible effects of insomnia symptoms on glycoprotein acetyls and citrate and longer total sleep duration on creatinine and isoleucine might explain some of the effects, found in MR analyses of these sleep traits on coronary heart disease, which warrant further investigation.Competing Interest StatementDOMK is a part-time research consultant at Metabolon, Inc. DAL has received research support from national and international government and charitable funders, as well as Roche Diagnostics and Medtronic for research unrelated to that presented here. All others declare no conflicts of interest.Funding StatementThis research was funded by the British Heart Foundation (AA/18/7/34219), Diabetes UK (17/0005700) and the European Research Council (DevelopObese, 669545), which funds NJGs salary. KHW is supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol and the Wellcome Trust Institutional Strategic Support Fund (204813/Z/16/Z). NJG, MAL, RCR, KHW and DAL work in a unit that receives support from the University of Bristol and UK Medical Research Council (MC_UU_00011/6). AD is funded by the Wellcome Trust (206046/Z/17/Z). RM is supported by the Presidents PhD scholarship from Imperial College, London. MAL is funded by a UK Medical Research Council PhD studentship (MR/R502340/1). DAL is a UK National Institute for Health Research Senior Investigator (NF-0616-10102). Sources of funding for individual studies used in this paper are listed in Supplemental Material.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Each participating study obtained written informed consent from all participants and received approval from the appropriate local institutional review boards.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRN and DAL act as guarantors for the paper.